Study Links Drug Burden to Kidney Injury in Cancer ICU

A retrospective study of 210 cancer patients in intensive care found acute kidney injury was associated with higher medication use and drug interactions.

Updated on Nov. 20, 2026 in Cancer

Isometric editorial illustration of unlabeled amber vials and IV bags stacked beside a matte gray kidney shape on a pale background, suggesting medication burden and kidney injury.
A retrospective study of 210 cancer ICU patients found acute kidney injury in 41% of cases, linked to higher medication burden and drug interactions. AI Illustration. Upload story photo >

A retrospective study of 210 adults with cancer treated in intensive care units at a tertiary care center found acute kidney injury in 86 patients, or 41.0%. The research was published in 2026 and associated the condition with higher medication burden and potential drug interactions.

Why it matters

Patients with acute kidney injury had higher in-hospital mortality, 39.5% versus 21.8% in those without it. The findings point to medication review as a possible way to identify cancer patients at greater risk of kidney damage.

The study reviewed 210 adults with cancer in a single center's ICUs, and patients with acute kidney injury took a median of 11 drugs versus 8 without it, with 10 or more distinct drugs linked to higher odds (aOR 2.62; 95% CI 1.32 to 5.18). Whether reducing medication burden would prevent kidney injury in these patients remains untested.

The details

Researchers staged acute kidney injury using KDIGO criteria and counted each patient's total and kidney-toxic drugs, screening for potential interactions with a standard database. Other independent predictors included a higher APACHE II score, chronic kidney disease, sepsis, and cisplatin exposure.

Timeline

  1. All patients had received anticancer therapy within 30 days before or during their ICU stay.

  2. The retrospective study was published in 2026.

Health Landscape

The study applies KDIGO acute kidney injury staging criteria to cancer patients in intensive care, extending existing kidney-injury research into the medication-burden question. Its findings add to the growing attention to polypharmacy and drug interactions as modifiable risks in complex oncology care.

Patients receiving cancer treatment in intensive care may benefit from careful medication reviews that account for total drug count and potential interactions. Clinicians and caregivers should discuss any new kidney-related warning signs with the treating team.

The takeaway

Reviewing the total number of medications and possible drug interactions may be a useful step for cancer patients with other kidney risk factors. Questions about personal medication safety should be raised with the treating oncology or critical care team.

Further reading

Explore more Cancer coverage on Wisevoter for related context on treatment-related complications.

Source note: This article includes information reported by European Medical Journal.